European Journal of Gastroenterology & Hepatology最新文献

{"title":"Efficacy of pancreatic enzyme replacement therapy on exocrine pancreatic insufficiency: a systematic review and meta-analysis.","authors":"Xiuming Yang, Lina Yang, Weiwei Zhang, Lixia Zhong, Yulin Zheng","doi":"10.1097/MEG.0000000000003225","DOIUrl":"10.1097/MEG.0000000000003225","url":null,"abstract":"<p><p>Exocrine pancreatic insufficiency (EPI) results in impaired digestion of fat, protein, and carbohydrates due to inadequate pancreatic enzyme secretion and is commonly managed with pancreatic enzyme replacement therapy (PERT). However, the extent to which PERT improves objective measures of nutrient absorption across different etiologies of EPI has not been fully clarified. A comprehensive search of PubMed/MEDLINE, Embase, Scopus, Web of Science, the Cochrane Library, and Google Scholar was performed from inception through December 2025. Randomized controlled trials (RCTs) comparing PERT with placebo in patients diagnosed with EPI were included. Eligible studies were required to report data on the coefficient of fat absorption (CFA) and the coefficient of nitrogen absorption (CNA). Data were pooled using a random-effects model, and standardized mean differences (SMDs) with 95% confidence intervals (CIs) were calculated. Subgroup, sensitivity, and publication bias analyses were performed. Fourteen RCTs involving 684 patients were included. PERT significantly improved fat absorption compared with placebo (CFA: SMD = 1.57, 95% CI: 1.20-1.94) and also enhanced protein absorption (CNA: SMD = 1.52, 95% CI: 0.97-2.06). Etiology-based subgroup analyses showed significant improvements in CFA among patients with cystic fibrosis (CF)-related EPI (SMD = 1.87, 95% CI: 1.48-2.25) and chronic pancreatitis-related EPI (SMD = 1.08, 95% CI: 0.67-1.49). Similarly, PERT significantly increased CNA in CF-associated EPI (SMD = 1.90, 95% CI: 1.30-2.50) and in EPI secondary to chronic pancreatitis (SMD = 0.74, 95% CI: 0.31-1.18). PERT substantially improves both fat and protein absorption in patients with EPI, with consistent efficacy across major etiological subgroups. These findings reinforce the role of enzyme replacement therapy as a cornerstone of EPI management and support its continued use to optimize digestive and nutritional outcomes.</p>","PeriodicalId":11999,"journal":{"name":"European Journal of Gastroenterology & Hepatology","volume":" ","pages":"1272-1284"},"PeriodicalIF":2.1,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148469545","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effectiveness of sodium-glucose cotransporter 2 inhibitors in patients with metabolic dysfunction-associated steatotic liver disease: systematic review and meta-analysis of randomized controlled trials.","authors":"Milena Ramos Tomé, Jingying Elena Chen, Alana Vitória Santos de Jesus, Wellgner Fernandes Oliveira Amador, Gustavo Procópio Silva, Igor Boechat Silveira, Arthur Victor de Holanda Sampaio, Guilherme Grossi Lopes Cançado","doi":"10.1097/MEG.0000000000003196","DOIUrl":"10.1097/MEG.0000000000003196","url":null,"abstract":"<p><p>Metabolic dysfunction-associated steatotic liver disease (MASLD) is highly prevalent and can progress to cirrhosis and hepatocellular carcinoma. Treatment options are still lacking. We assessed the efficacy of sodium-glucose cotransporter 2 inhibitors (SGLT2i) in MASLD. An updated systematic review and meta-analysis of randomized controlled trials in PubMed, Embase, and Cochrane comparing SGLT2i with placebo or active drugs were conducted. Primary outcomes were controlled attenuation parameter (CAP) and liver stiffness by elastography, and fibrosis-4 (FIB-4) score; secondary outcomes were liver enzymes, metabolic and anthropometric measures, and MRI-PDFF. A subgroup without diabetes mellitus (DM) was analyzed. Twenty-nine randomized clinical trials were included ( n  = 2443). SGLT2i use significantly reduced liver stiffness [mean difference (MD): -0.47 kPa; 95% confidence interval (CI): -0.88 to -0.07; P  = 0.022; I2 =75%], CAP (MD: -12.24 dB/m; 95% CI: -20.12 to -4.35; P  = 0.002; I2 =1%), and FIB-4 (MD: -0.22; 95% CI: -0.38 to -0.06; P  = 0.008; I2 =84%). Improvements were consistently observed in liver enzymes, including alanine aminotransferase, aspartate aminotransferase, and gamma-glutamyl transferase. In addition, reductions were noted in body weight, visceral adipose tissue, waist circumference, glycated hemoglobin, and homeostatic model assessment of insulin resistance. In the subgroup analysis of patients without DM ( n  = 257), SGLT2i also significantly reduced aspartate aminotransferase and gamma-glutamyl transferase, as well as anthropometric parameters. SGLT2i improves hepatic, metabolic, and anthropometric parameters in MASLD, including liver stiffness, steatosis, and FIB-4; benefits also occur in non-DM individuals, warranting further trials.</p>","PeriodicalId":11999,"journal":{"name":"European Journal of Gastroenterology & Hepatology","volume":" ","pages":"1254-1271"},"PeriodicalIF":2.1,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148053416","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Diagnostic performance of endoscopic ultrasound and conventional cyst fluid analysis in pancreatic cystic lesions without molecular testing: a real-world, guideline-based study.","authors":"Ümit Karaoğullarindan, Kaan Nisanoğlu, Nuri Kollu, Meltem Süngü, Emre Odabaş, Hasan Selim Güler, Sadik Dincer, Anil Delik, Asena Ayça Özdemir, Yüksel Gümürdülü","doi":"10.1097/MEG.0000000000003226","DOIUrl":"10.1097/MEG.0000000000003226","url":null,"abstract":"<p><strong>Background: </strong>Differentiating mucinous from non-mucinous pancreatic cystic lesions (PCLs) remains clinically challenging because of overlapping imaging features and heterogeneous malignant potential. Although molecular cyst fluid analysis improves diagnostic accuracy, its limited availability and high cost restrict routine use. This study aimed to evaluate the diagnostic performance of endoscopic ultrasound (EUS) morphology combined with conventional cyst fluid analysis in a real-world, guideline-based cohort without molecular testing.</p><p><strong>Methods: </strong>In this retrospective cohort study, 100 consecutive patients with PCLs underwent EUS-guided cyst fluid sampling. EUS morphology and cyst fluid carcinoembryonic antigen (≥192 ng/mL), glucose (≤50 mg/dL), cytology, and string sign were systematically assessed. Final diagnoses were established through multidisciplinary clinical-radiological follow-up of at least 12 months. Of the included patients, 38 cysts were classified as mucinous and 62 as non-mucinous.</p><p><strong>Results: </strong>Among individual biomarkers, cyst fluid glucose demonstrated the highest sensitivity for identifying mucinous cysts (89.5%), while cytology and the string sign showed the highest specificity (98.4 and 95.2%, respectively). EUS morphology alone achieved moderate diagnostic performance (sensitivity 71.1%, specificity 77.4%). Combining EUS morphology with cyst fluid analysis significantly improved diagnostic accuracy, with sensitivities and specificities of 92.1 and 88.7% for EUS plus greater than or equal to 1 marker, and 94.7 and 90.3% for EUS plus greater than or equal to 2 markers, respectively.</p><p><strong>Conclusion: </strong>A multimodal, guideline-based approach integrating EUS morphology with conventional cyst fluid analysis provides clinically meaningful diagnostic accuracy for differentiating PCLs in real-world settings without molecular testing. This pragmatic strategy is particularly valuable in centers where molecular diagnostics are unavailable.</p>","PeriodicalId":11999,"journal":{"name":"European Journal of Gastroenterology & Hepatology","volume":" ","pages":"1299-1304"},"PeriodicalIF":2.1,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148976223","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comment on PIVKA-II in resected hepatocellular carcinoma.","authors":"Zilong Chen, Xiangrui Lin, Mingxian Chen","doi":"10.1097/MEG.0000000000003270","DOIUrl":"https://doi.org/10.1097/MEG.0000000000003270","url":null,"abstract":"","PeriodicalId":11999,"journal":{"name":"European Journal of Gastroenterology & Hepatology","volume":"38 11","pages":"1367-1368"},"PeriodicalIF":2.1,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149105600","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical trends in hepatocellular carcinoma from 2005 to 2019 with a focus on metabolic diseases: a German nationwide study.","authors":"Josune Cabello, Wenyi Gu, Robert Schierwagen, Maximilian Joseph Brol, Frank Erhard Uschner, Martin Sebastian McCoy, Sabine Klein, Kai-Henrik Peiffer, Dominik Van de Loo, Andreas Pascher, Martina Holstein, Felix Becker, Haluk Morgül, Michael Köhler, Max Masthoff, Inga Grünewald, Klaus Wethmar, Dominik Heider, Michael Praktiknjo, Anton Gillessen, Florian Rennebaum, Jonel Trebicka","doi":"10.1097/MEG.0000000000003278","DOIUrl":"10.1097/MEG.0000000000003278","url":null,"abstract":"<p><strong>Introduction: </strong>Hepatocellular carcinoma (HCC) is the leading primary liver cancer and is associated with a high mortality rate. Liver cirrhosis represents the main risk factor for HCC; however, its underlying etiologies have shifted over the last decade. This German population-based study investigated the effects of the changing trends on etiologies of HCC hospital admissions.</p><p><strong>Methods: </strong>We analyzed 369 369 HCC-admissions in German hospitals from 2005 to 2019 based on the diagnosis-related groups via German International Classification of Diseases and Operation and Procedure key System codes. Temporal trends and associations were assessed using linear and multivariate logistic regression.</p><p><strong>Results: </strong>HCC admissions increased significantly by 21.8%, from 19 594 in 2005 to 25 899 in 2019, while the in-hospital mortality rate decreased from 13.6 to 10.8%. The most common underlying etiology was alcohol-related liver disease (ALD), accounting for 55.5% of all HCC etiologies, followed by viral hepatitis (32.3%). While admissions of patients with ALD increased by 34.5% from 4008 to 5392, viral hepatitis declined significantly from 3532 to 1580. Metabolic dysfunction-associated steatotic liver disease (MASLD) underlying for HCC represented 4.5%, but exhibited the strongest increase of 3.7-fold among all etiologies. The in-hospital mortality rate of ALD-associated HCC decreased from 15.3 to 11.6%, whereas in viral hepatitis-associated HCC, it remained more similar (11.5 vs. 11.0%). Cardiometabolic risk factors significantly increased in HCC admissions over time ( P < 0.001). Furthermore, HCC admissions exhibited a greater burden of metabolic comorbidities than other malignancies.</p><p><strong>Conclusions: </strong>This study highlights the increase in underlying ALD, MASLD, and metabolic risk factors in HCC admissions. Especially, cardiometabolic risk factors appear to play a significant role as drivers of hospital admissions in patients with HCC.</p>","PeriodicalId":11999,"journal":{"name":"European Journal of Gastroenterology & Hepatology","volume":" ","pages":"1339-1349"},"PeriodicalIF":2.1,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149012153","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A meta-analysis of transjugular intrahepatic portosystemic shunt with or without embolization for esophageal and gastric variceal bleeding in decompensated liver cirrhosis.","authors":"Xiongtao Ma, Xinyan Yu, Qingping Wu, Yu Chen, Ting Jiang, Lei Wang, Qinghua Tao","doi":"10.1097/MEG.0000000000003280","DOIUrl":"10.1097/MEG.0000000000003280","url":null,"abstract":"<p><strong>Background: </strong>This study aimed to evaluate whether transjugular intrahepatic portosystemic shunt (TIPS) combined with embolization could further improve efficacy for patients with decompensated liver cirrhosis complicated with esophageal and gastric variceal bleeding.</p><p><strong>Methods: </strong>We searched PubMed, Web of Science, Embase, and Cochrane Library, for all relevant randomized controlled trials and cohort studies up to March 2025. Statistical results were evaluated using risk ratios and 95% confidence intervals (CIs).</p><p><strong>Results: </strong>A total of 14 studies involving 3079 patients were included. The statistical results showed that the rebleeding rate in the TIPS combined with embolization group was lower than that in the TIPS alone group (risk ratios = 0.67; 95% CI = 0.57-0.79; P  < 0.001), and the same result was observed only in the subgroup of patients with gastric variceal bleeding (risk ratios = 0.50; 95% CI = 0.34-0.74; P  < 0.001). There was no significant difference between the groups in patients with isolated esophageal variceal bleeding (risk ratios = 0.83; 95% CI = 0.51-1.35; P  = 0.46). In addition, the incidence of hepatic encephalopathy in the TIPS combined with embolization group was also lower than that in the TIPS alone group (risk ratios = 0.82; 95% CI = 0.73-0.91; P  < 0.001), but there was no significant difference in survival rate (risk ratios = 1.00; 95% CI = 0.97-1.03; P  = 0.94).</p><p><strong>Conclusion: </strong>Compared with TIPS alone, the combined treatment showed a trend toward lower rebleeding and hepatic encephalopathy, yet survival appeared similar between the two groups.</p>","PeriodicalId":11999,"journal":{"name":"European Journal of Gastroenterology & Hepatology","volume":" ","pages":"1350-1357"},"PeriodicalIF":2.1,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149012204","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Factors associated with preference for in-person versus remote consultations in inflammatory bowel disease in the United Kingdom: secondary analysis of an online survey.","authors":"Keith Bodger, Frederick Taylor, Pratik Rai, Liz Dobson, Judith Bunn, Stephen Grainger, Fraser Cummings, Stuart Bloom, Nicholas Kennedy","doi":"10.1097/MEG.0000000000003220","DOIUrl":"10.1097/MEG.0000000000003220","url":null,"abstract":"<p><strong>Introduction: </strong>The coronavirus disease 2019 pandemic accelerated use of remote consultations as an alternative to in-person inflammatory bowel disease (IBD) care. However, factors associated with preference for remote or in-person follow-up remain poorly understood.</p><p><strong>Methods: </strong>We undertook a retrospective analysis of an electronic follow-up survey completed by patients who had previously used an online IBD self-assessment tool during the early pandemic. Respondents with prior experience of remote consultations were included. Preference for future consultation modality was categorised as strong in-person preference ('Never by telephone or video'), strong remote preference ('Mostly by telephone or video'), or no preference. Survey domains included sociodemographics, comorbidities, home restriction, mobility, support, IBD-Control Questionnaire, patient reported outcome-2 symptoms, and satisfaction with IBD care. Associations with preference were examined using binary logistic regression and ordinal logistic regression across ordered preference categories from remote to no preference to in-person.</p><p><strong>Results: </strong>Among 5833 eligible respondents, 65% reported no preference, 25% a strong remote preference, and 10% a strong in-person preference. Stronger in-person preference was associated with older age, male gender, greater area deprivation, Asian ethnicity compared with White ethnicity, two or more comorbidities, Crohn's disease compared with ulcerative colitis, poorer IBD-specific patient-reported outcome measures, higher patient reported outcome-2 symptom scores, and dissatisfaction with care. Associations with strong remote preference were generally opposite, including younger age, lower deprivation, fewer comorbidities, ulcerative colitis, better patient reported outcome measure scores, and greater satisfaction; gender and ethnicity were not significant. Home restriction, mobility, and support were not significantly associated. Negative IBD-Control-8 responses increased progressively from remote preference to no preference to in-person preference.</p><p><strong>Conclusion: </strong>Sociodemographic and clinical factors influence consultation preferences in IBD. These findings may support equitable integration of remote care models.</p>","PeriodicalId":11999,"journal":{"name":"European Journal of Gastroenterology & Hepatology","volume":" ","pages":"1290-1298"},"PeriodicalIF":2.1,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13626586/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148469596","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comments on 'Cardiovascular risk profiles in patients with primary sclerosing cholangitis'.","authors":"Sarosh Ansar, Raj Bhawish","doi":"10.1097/MEG.0000000000003267","DOIUrl":"https://doi.org/10.1097/MEG.0000000000003267","url":null,"abstract":"","PeriodicalId":11999,"journal":{"name":"European Journal of Gastroenterology & Hepatology","volume":"38 11","pages":"1365"},"PeriodicalIF":2.1,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149105791","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Management of endoscopic rectal activity in ulcerative colitis: real-world adherence to guidelines and clinical outcomes.","authors":"Athanasios Malkopoulos, Deloshaan Subhaharan, Rayshelle James, Mark Jones, Pradeep Kakkadasam Ramaswamy, Waled Mohsen","doi":"10.1097/MEG.0000000000003228","DOIUrl":"10.1097/MEG.0000000000003228","url":null,"abstract":"<p><strong>Objective: </strong>Rectal disease activity in ulcerative colitis is associated with a high symptom burden. The British Society of Gastroenterology (BSG) provides evidence-based recommendations for the management of ulcerative proctitis, which are relevant to patients with rectal disease activity; however, real-world adherence and outcomes remains unclear. This study aimed to evaluate adherence to BSG guideline-recommended management and its relationship with treatment timing and clinical outcomes.</p><p><strong>Methods: </strong>We conducted a retrospective observational cohort study at a single tertiary center (2022-2024). Adults with endoscopically confirmed rectal disease activity in ulcerative colitis were included. Guideline adherence was assessed using predefined criteria derived from the BSG algorithm. Clinical, biochemical, endoscopic, and histological remission were evaluated at 12 months.</p><p><strong>Results: </strong>Of 119 patients, 63 (52.9%) received guideline-adherent management. Adherence was significantly higher when treatment decisions were made at endoscopy compared with deferral to clinic (73 vs. 22%, RR: 0.30, 95% CI: 0.16-0.51; P  < 0.001). At 12 months, clinical remission was achieved in 97/119 (81.5%), biochemical remission in 80/96 (83.3%), endoscopic remission in 36/68 (52.9%), and histological remission in 30/68 (44.1%). Guideline-adherent management showed numerically higher clinical remission rates, though not statistically significant. Deferral of treatment decisions was associated with a lower rate of clinical remission (72 vs. 86%), although not statistically significant ( P  = 0.06).</p><p><strong>Conclusion: </strong>Guideline adherence is suboptimal in real-world practice. Endoscopy-led decision-making were strongly associated with guideline adherence and represents a modifiable system-level factor in care delivery. High overall remission rates suggest that guideline adherence alone may be an incomplete surrogate for care quality.</p>","PeriodicalId":11999,"journal":{"name":"European Journal of Gastroenterology & Hepatology","volume":" ","pages":"1311-1318"},"PeriodicalIF":2.1,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148469580","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Percutaneous catheter drainage versus needle aspiration for liver abscess: a systematic review and meta-analysis of efficacy and safety.","authors":"Dandan Xu, Deying Zeng","doi":"10.1097/MEG.0000000000003252","DOIUrl":"10.1097/MEG.0000000000003252","url":null,"abstract":"<p><strong>Background: </strong>Percutaneous catheter drainage (PCD) and percutaneous needle aspiration (PNA) are the two primary image-guided interventions for liver abscesses. However, their comparative efficacy and safety profiles remain debated.</p><p><strong>Methods: </strong>We systematically searched PubMed, Embase, Web of Science, and the Cochrane Library for randomized controlled trials (RCTs) directly comparing PCD and PNA in adults with liver abscesses. The primary outcomes were clinical treatment success rate and procedure-related complication rate. Data were pooled using random-effects models, and heterogeneity was assessed with the I2 statistic.</p><p><strong>Results: </strong>Twelve RCTs involving 1425 patients were included. Meta-analysis showed that PCD was associated with a significantly higher treatment success rate compared to PNA [odds ratio (OR) = 4.12, 95% confidence interval (CI) = 2.01-8.45; P  < 0.001; I2  = 56%]. Subgroup analyses by abscess size and etiology confirmed the consistency of this benefit. There was no statistically significant difference in the overall complication rates between the two procedures (OR = 1.02, 95% CI = 0.30-3.50; P  = 0.97; I2  = 46%).</p><p><strong>Conclusion: </strong>For the treatment of liver abscesses, PCD is superior to needle aspiration in achieving clinical success without increasing the risk of procedure-related complications. PCD should be considered the preferred percutaneous drainage technique.</p>","PeriodicalId":11999,"journal":{"name":"European Journal of Gastroenterology & Hepatology","volume":" ","pages":"1329-1338"},"PeriodicalIF":2.1,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148976303","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}